➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Dow
Colorcon
Moodys
Boehringer Ingelheim

Last Updated: February 28, 2021

DrugPatentWatch Database Preview

Generic Companies with Tentative Approvals for: Par Pharm Inc

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Par Pharm Inc Generic Filers with Tentative Approvals

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Applicant Generic Name NDA Strength Dosage Form
Par Pharm Inc lurasidone hydrochloride 207948 40MG TABLET;ORAL
Par Pharm Inc milnacipran hydrochloride 205062 12.5MG TABLET;ORAL
Par Pharm Inc lurasidone hydrochloride 207948 120MG TABLET;ORAL
>Applicant >Generic Name >NDA >Strength >Dosage Form

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Harvard Business School
Boehringer Ingelheim
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.